Direct to Consumer Biomarker Testing for Alzheimer Disease—Are We Ready for the Insurance Consequences? JJ Arias et al, JAMA Neurology, December 18, 2023

https://phgkb.cdc.gov/PHGKB/phgHome.action?action=archive&date=12/18/2023 From the article: "The promise of DTC testing for AD biomarkers may be lauded by advocates pushing for earlier diagnoses and individuals’ right to know. Early diagnosis of AD through DTC or clinical evaluations could provide benefits, including increased monitoring and preventive care. Additionally, DTC tests could reduce barriers that impede a timely diagnosis (eg, access to dementia specialists). However, DTC tests are not without hazard, particularly given gaps in discriminatory protections for individuals at risk of developing AD with known biomarker status. "